Refining Treatment Decisions in HCV-Infected Patients with Decompensated Cirrhosis: Frequency and Predictors of Recompensation with Direct-Acting Antiviral (DAA) Therapy

被引：0
|
作者：
Radhakrishnan, Kavita [1 ]
Dodge, Jennifer L. [2 ]
McKinney, Jeff [1 ]
Catalli, Lisa [1 ]
Straley, Stephanie [3 ]
Price, Jennifer C. [4 ]
Terrault, Norah [4 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Surg, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Liver Transplant, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1227
引用
收藏
页码：712A / 712A
页数：1
相关论文
共 50 条
  • [31] Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
    Hanafy, Amr Shaaban
    Bassiony, Mohamed A.
    Basha, Mohammad Abd Alkhalik
    HEPATOLOGY INTERNATIONAL, 2019, 13 (02) : 165 - 172
  • [32] Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy
    Avik Majumdar
    Matthew T. Kitson
    Stuart K. Roberts
    Drugs, 2015, 75 : 823 - 834
  • [33] HCV REINFECTION AFTER SUCCESSFUL TREATMENT WITH DIRECT-ACTING ANTIVIRAL THERAPY (DAA) IN PEOPLE WHO INJECT DRUGS (PWID)
    Patsi, Marina
    Koustenis, Kanellos-Rafail
    Kranidioti, Hariklia
    Fylaktos, Panagiotis
    Vasileiadi, Sofia
    Antonakaki, Pinelopi
    Koutli, Evangelia
    Deutsch, Melanie
    Anagnostou, Olga
    Manolakopoulos, Spilios
    GASTROENTEROLOGY, 2021, 160 (06) : S825 - S825
  • [34] Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy
    Majumdar, Avik
    Kitson, Matthew T.
    Roberts, Stuart K.
    DRUGS, 2015, 75 (08) : 823 - 834
  • [35] Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis
    Xia, Huan
    Zhang, Yaping
    Zaongo, Silvere D.
    Liang, Jing
    Gong, Xiaowen
    Hu, Yue
    Ma, Ping
    Wang, Fengmei
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (10)
  • [36] A Study on the Prevalence of HCV Genotypes and the Effect of Direct-Acting Antiviral Therapy on Clinical and Laboratory Parameters in HCV-Infected Patients at a Tertiary Care Center in North India
    Shahanas, S. Muhammed
    Verma, Rajeev
    Kumar, Kanishka
    Verma, Manisha
    Srivastavsa, Deepak Chandra
    Budhwani, Priyanka
    INDIAN JOURNAL OF COMMUNITY MEDICINE, 2024, 49 (01) : 203 - 208
  • [37] Evaluation of APRI index to identify cirrhosis prior to direct-acting antiviral HCV treatment
    Doyle, J.
    Harney, B.
    Brainard, D.
    Osinusi, A.
    Stamm, L.
    Hellard, M.
    Thompson, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S313 - S314
  • [38] HCV Infection/Cirrhosis: Effects of Direct-acting Antiviral Treatment studied at the Population Level
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (01): : 12 - 12
  • [39] Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A Systematic Review and Meta-Analysis
    An, JiHyun
    Park, Dong Ah
    Ko, Min Jung
    Ahn, Sang Bong
    Yoo, Jeong-Ju
    Jun, Dae Won
    Yim, Sun Young
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (09):
  • [40] Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
    Flisiak, Robert
    Zarebska-Michaluk, Dorota
    Berak, Hanna
    Dybowska, Dorota
    Sitko, Marek
    Parfieniuk-Kowerda, Anna
    Janocha-Litwin, Justyna
    Janczewska, Ewa
    Piekarska, Anna
    Lorenc, Beata
    Mazur, Wlodzimierz
    Dobrowolska, Krystyna
    Tudrujek-Zdunek, Magdalena
    Klapaczynski, Jakub
    Jaroszewicz, Jerzy
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 193 - 201
12345